Synergistic interaction enhances pathogenesis of Parkinson's disease

Dec 23, 2009

Scientists have identified a synergistic interaction that disrupts normal intracellular transport mechanisms and leads to the accumulation of neuron-damaging clumps of protein associated with Parkinson's disease (PD), a neurodegenerative disorder that is characterized by a specific loss of neurons in the midbrain and brainstem. The research, published by Cell Press in the December 24 issue of the journal Neuron, identifies a new potential therapeutic option for preventing PD-associated neuropathology.

Mutations in the α-synuclein ( α-syn) and Leucine-rich repeat kinase (LRRK2) genes have been linked with inherited and sporadic forms of PD and previous research has shown that accumulation of cytotoxic α-syn protein inside of neurons represents a key step in the pathogenesis of PD. "Although earlier studies have suggested interplay between α-syn and LRRK2, a synergistic interaction in the pathogenesis of PD has not been established," explains senior study author Dr. Huaibin Cai from the Laboratory of Neurogenetics at the National Institutes of Health in Bethesda, Maryland.

In order to systematically investigate whether LRRK2 and α-syn act synergistically to potentiate PD, Dr. Cai and colleagues generated and characterized several types of that overexpressed different combinations of a PD-related α-syn mutation along with various forms of normal and PD-associated LRRK2. The researchers found that although overexpression of LRRK2 alone did not cause neurodegeneration, excess LRRK2 significantly accelerated the progression of neuropathological abnormalities in transgenic mice expressing PD-related α-syn.

Overexpression of LRRK2 disrupted key structures and mechanism that play a role in transporting proteins inside of the neurons. Importantly, genetic disruption of LRRK2 maintained normal intracellular transport and reduced the accumulation of α-syn, thereby significantly delaying the progression of PD pathology in the PD α-syn transgenic mice. These findings suggest that LRRK2 exacerbates the abnormal intracellular accumulation of α-syn.

"We have uncovered a novel function for LRRK2 in regulating the intracellular trafficking and accumulation of α-syn in and our results suggest that excessive amounts of LRRK2 or its mutants may result in abnormal neuron-damaging accumulation of α-syn ," concludes Dr. Cai. "It is possible that inhibition of LRRK2 expression may provide an applicable therapeutic strategy to ameliorate α-syn-induced neurodegeneration in PD or other related neurodegenerative diseases."

Explore further: Facebook sues law firms, claims fraud

More information: “Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson’s-Disease-Related Mutant α-synuclein.” Publishing in Neuron 64, 807-827, December 24, 2009. DOI 10.1016/j.neuron.2009.11.006 www.neuron.org

add to favorites email to friend print save as pdf

Related Stories

Lessons from yeast: A possible cure for Parkinson's disease?

Aug 14, 2008

Parkinson disease (PD) is a debilitating and lethal neurodegenerative disease, for which there is currently no cure. It is caused by the progressive loss of nerve cells that produce the chemical dopamine and is characterized ...

Parkinson's mutation stunts neurons

Nov 22, 2006

Mutations in a key brain protein known to underlie a form of Parkinson's disease wreaks its damage by stunting the normal growth and branching of neurons, researchers have found. They have pinpointed the malfunction of the ...

Tracing Parkinson's lethal mechanism

Jul 05, 2007

In the vast majority of Parkinson’s disease (PD) patients, the disorder arises not because of a genetic defect, but because some external insult triggers the death of dopamine-producing neurons. Now, researchers have reported ...

Recommended for you

Facebook sues law firms, claims fraud

2 hours ago

Facebook is suing several law firms that represented a man who claimed he owned half of the social network and was entitled to billions of dollars from the company and its CEO Mark Zuckerberg.

IBM 3Q disappoints as it sheds 'empty calories'

2 hours ago

IBM disappointed investors Monday, reporting weak revenue growth again and a big charge to shed its costly chipmaking division as the tech giant tries to steer its business toward cloud computing and social-mobile ...

User comments : 0